Croma-Pharma Achieves First MDR Approval in Aesthetics

Croma-Pharma is the first company worldwide to achieve MDR approval in the aesthetic field.

Croma-Pharma, has become the first industry company to achieve European certification under the Medical Device Regulation (MDR) 2027/745 for aesthetic purposes.

The technical and clinical documentation was reviewed and approved by the renowned body TÜV Süd (CE0123), meaning that “Saypha® RICH” is the first of a total of seven Croma-Pharma product groups to successfully complete the strict MDR certification process. All other products from the Saypha® range will be approved by the first quarter of 2024.

“Croma is setting new standards in the field of aesthetic medicine with the MDR approval of our dermal fillers. We are proud to be the first company in the industry to comply with the strict requirements of the new EU Medical Devices Regulation. The certification is an important milestone in our company history and at the same time clear confirmation of our commitment to provide our customers with the safest and highest quality products.”

Andreas Prinz, Managing Director of Croma-Pharma

The new regulation replaces the current Medical Devices Directive (93/42/EEC) and aims to create a transparent, sustainable and internationally recognised regulatory framework that improves the clinical safety of products and allows fair market access to manufacturers.

MDR approval brings numerous advantages to patients and healthcare professionals (HCPs):

✓ Aesthetic indication: Enables the certification of products with aesthetic intended use in compliance with specific rules for risk management, labelling and information for use. This will allow us to offer our customers products with non-medical aesthetic purpose.

✓ Safety of the patient: Products that are CE-marked according to the MDR are subject to the strictest safety requirements and stricter monitoring. To remain on the market, existing products must undergo an MDR review.

✓ Clinical evidence: MDR safety and performance compliance must be demonstrated by clinical evidence.  Clinical trials conducted to provide this evidence are subject to stricter and more detailed requirements. 

✓ Labelling: MRD CE labelling requirements include more detailed information about the nature and use of the product, potential side effects, and safety and performance information based on clinical data.

✓ Transparency: The Unique Device Identification (UDI) system improves trackability of medical devices in the supply chain. A central EUDAMED database enables identification of products, their manufacturers and certifications, and provides a summary of safety and clinical capacity which is publicly available for each product.

“In an ever-changing market and with new legislation on the horizon, this is an accolade for

Croma-Pharma and further strengthens our commitment for setting standards in the aesthetic industry.”

Vikki Baker, Head of Marketing UK|IRE|NL